{"disease":{"id":"human-african-trypanosomiasis","name":"human african trypanosomiasis"},"drugs":{"marketed":[{"drug_id":"fexinidazole","indication_name":"Human African Trypanosomiasis (HAT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fexinidazole","generic_name":"FEXINIDAZOLE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":49,"revenue":null,"mechanism":"Fexinidazole works by releasing free radicals that damage the DNA of Trypanosoma brucei gambiense, ultimately killing the parasite."},{"drug_id":"fexinidazole","indication_name":"Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fexinidazole","generic_name":"FEXINIDAZOLE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":49,"revenue":null,"mechanism":"Fexinidazole works by releasing free radicals that damage the DNA of Trypanosoma brucei gambiense, ultimately killing the parasite."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04099628","title":"Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring","phase":"NA","overall_status":"COMPLETED","enrollment_count":13747,"lead_sponsor_name":"Institut de Recherche pour le Developpement","has_results":false},{"nct_id":"NCT06356974","title":"Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":false},{"nct_id":"NCT05637632","title":"Assessment of Recombinant HAT-RDT Specificity","phase":"","overall_status":"COMPLETED","enrollment_count":1504,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT05466630","title":"Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis","phase":"NA","overall_status":"COMPLETED","enrollment_count":1095,"lead_sponsor_name":"Institut de Recherche pour le Developpement","has_results":false},{"nct_id":"NCT02169557","title":"Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":false},{"nct_id":"NCT02184689","title":"Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":false},{"nct_id":"NCT03394976","title":"Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}